Expert Panel Formed to Determine Compensation to Patients Who Have Faulty Hip Implants
The Union Health Ministry has asked states and union territories to constitute separate committees so that they can receive such complaints from affected patients.
A Johnson & Johnson building in Irvine, California, US. REUTERS
New Delhi: The Centre has constituted a five-member expert committee to determine the quantum of compensation to be given to patients who have "faulty" hip implants, manufactured by DePuy International, a subsidiary of Johnson and Johnson.
Apart from the five-member expert panel, the Union Health Ministry has also asked states and union territories to constitute separate committees so that they can receive such complaints from affected patients.
In a letter, the ministry has also asked the states and UTs to bring out advertisements in newspapers so that the affected patients can approach the state-level committee or the state drug controller concerned.
The move comes after a panel, constituted earlier by the Union Health Ministry to investigate complaints about articular surface replacement (ASR) hip implant devices, said in its report that the pharma giant "suppressed" facts on the harm of surgeries afterwards which was conducted on patients in India using "faulty" hip replacement systems.
It had also suggested that the company pay compensation of around Rs 20 lakh to the affected patients. Some of the patients who had suffered due to the faulty implants had questioned the panel's recommendation of the paltry amount, saying it was like "rubbing salt on the wounds".
Now the Health Ministry, in its order dated August 30, has asked the central expert committee to submit its recommendation to the Central Drugs Standard Control Organisation (CDSCO) within 45 days of receiving recommendations from the state-level panels.
The order said a committee under the Chairmanship of Arun Kumar Aggarwal has given its report which has been accepted by the central government with certain modifications.
"Now the central government has decided to constitute a central expert committee to determine the quantum of compensation, as admissible under the law, in respect of faulty ASR hip implants manufactured by M/s DePuy International Limited, UK and implanted in India," the order said.
The five-member committee will be chaired by R K Arya, director, Sports Injury Centre, Safdurjung Hospital. C S Yadav, department of Orthopaedics, AIIMS in New Delhi; Vineet Sharma, HOD, Department of Orthopaedics, King George's Medical University in Lucknow; Bikas Medhi, professor pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh; and Bhushan Tilak Kaul, professor of law in Delhi University, will be its members.
"The committee may co-opt any other member and invite other experts to assist it in the examination of the matter," the order said.
According to reports, the expert committee findings say that over 3,600 patients with the faulty implants remain untraceable, and that at least four deaths have been reported from those who underwent surgeries using these devices.
Spelling out the terms of reference of the committee, the ministry order said, "(The committee will) review the report of state level committee or the applications submitted by affected patients and recommend quantum of compensation, as admissible under appropriate law, and medical management, if any, based on criteria suggested in the Dr. Arun Kumar Aggarwal Committee report subject to the modifications accepted by the Central Government."
It was earlier reported by PTI that the Health Ministry has directed the formation of committees at the state level to receive such complaints from affected patients.
"...action by state governments and UTs is required on the following points - constitution of state level committee...which should comprise two orthopaedic surgeons or physical medical rehabilitation experts from government medical college and hospital, one radiologists from government hospital and a Central Drugs Standard Control Organisation (CDSCO) zonal or sub-zonal office representative and drug controller of respective state as member secretary.
"Advertisements are to be brought out by respective state governments/UTs in newspapers so that affected persons can approach the state level committee or the concerned state drug controller who would be the member secretary of the committee," the letter to states said.
Drugs Controller General of India Eswara Reddy told PTI, "Once the state committee assess the grievance of the patients, they can give their recommendations to the central expert committee which has been formed. Once the five-member central expert committee gives its recommendations, we can take the process of providing compensation forward."
Support the daily wage earners who have been hit the hardest by the COVID-19 crisis. Click here to contribute to the cause. #IndiaGives
The daily News18 Coronavirus COVID-19 newsletter - Get your copy here.
Recommended For You
- The Virus And Face With a Mask Are The Most Popular Emojis in COVID Conversations
- This Electric HM Ambassador Rendered by DC2 Makes Us Wish it Was a Reality
- Salman Khan's Radhe Crew Member Confirms Actor Deposited Money into Their Accounts Despite No Shoot
- Apple iPhone 9 Launch Likely Pegged for April 15, Sale May Kick Off on April 22
- Disney+ Hotstar Subscription Costs More Than Hotstar Premium: Here’s Why